In this article, we describe the synthesis of N3‐methyluridine (m3U) and 2′‐O‐alkyl/2′‐fluoro‐N3‐methyluridine (2′‐O‐alkyl/2′‐F‐m3U) phosphoramidites as well as their incorporation into a 14‐mer DNA and RNA oligonucleotide sequence. Synthesis of the 2′‐O‐alkyl‐m3U phosphoramidite starts with commercially available uridine to achieve a tritylated m3U intermediate, followed by 2′‐O‐alkylation and finally phosphitylation. Synthesis of the 2′‐F‐m3U phosphoramidite is obtained from a commercially available 2′‐F‐uridine nucleoside. These phosphoramidite monomers are compatible with DNA and RNA oligonucleotide synthesis using conventional phosphoramidite chemistry. This strategy offers efficient synthetic access to various modifications at the 2′‐position of m3U that can be employed in numerous nucleic acid–based therapeutic applications, including antisense technologies, small interfering RNAs, CRISPR‐Cas9, and aptamers. The data presented in this article are based on our previously published reports. © 2024 Wiley Periodicals LLC.Basic Protocol 1: Synthesis of 2′‐O‐alkyl‐N3‐methyluridine analogs and their corresponding phosphoramiditesAlternate Protocol 1: Synthesis of 2′‐O‐TBDMS‐N3‐methyluridine and its phosphoramiditeAlternate Protocol 2: Synthesis of 2′‐fluoro‐N3‐methyluridine and its phosphoramiditeBasic Protocol 2: Solid‐phase synthesis of N3‐methyluridine‐modified DNA and RNA oligonucleotides